The Quantellect read.As of Nov 19, 2026, 11 active firms cover Relay Therapeutics Inc: 10 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $18.00 to $31.00, a moderate spread. The average target of $25.91 sits 57% above the current $16.51. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.38 next quarter toward $-1.57 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy19%
Buy982%
Neutral19%
Sell00%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$25.91
+56.9% upside
Average target across 11 active firms as of Nov 19, 2026 vs $16.51 current
Highest Target$31.00
Average Target$25.91
Lowest Target$18.00
Detailed analyst forecasts for RLAY
Showing 1–11 of 11 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 10 of 11 active firms rate RLAY a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
RLAY EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.41 – $-0.35 · 5 analysts · -6% YoY
Next period, 5 analysts expect Relay Therapeutics Inc to earn $-0.38 a share (range $-0.41 – $-0.35), versus $-0.41 a year earlier. Full-year consensus is $-1.56, growing to $-1.57 the year after.
REVENUE · NEXT QUARTER
$720.0K
Range $0 – $2.0M · 5 analysts · -76% YoY
Revenue is expected to reach $720.0K (range $0 – $2.0M), -76.0% year-over-year. Full-year consensus is $6.9M, rising to $10.6M next year.
Top analysts covering Relay Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RLAY.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$10.00-39.4% to target
Overall win rate
53%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #69
Buy
$26.00+57.5% to target
Overall win rate
51%
+ Follow
#3
Andrew Berens
Leerink Partners · Rank #162
Buy
$12.00-27.3% to target
Overall win rate
53%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$29.00+75.7% to target
Overall win rate
42%
+ Follow
#5
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$26.00+57.5% to target
Overall win rate
39%
+ Follow
RLAY stock forecast FAQ
What is RLAY's average 12-month price target?+
The 11 active firms with a live target average $25.91 for Relay Therapeutics Inc over the next 12 months, ranging from a $31.00 high to a $18.00 low, as of Nov 19, 2026.
Is RLAY stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for RLAY?+
The Street-high target is $31.00 (JP Morgan), and the Street-low is $18.00 (Oppenheimer). The average of all 11 active-firm targets is $25.91.
How many active Wall Street firms cover RLAY?+
11 active firms have a recognized rating on Relay Therapeutics Inc as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering RLAY?+
Among analysts who currently cover RLAY, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $10.00 target.
What is Relay Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.41 – $-0.35) across 5 analysts. Full-year EPS is projected at $-1.56, rising to $-1.57 the following year.
How much revenue is Relay Therapeutics Inc expected to report next quarter?+
Consensus revenue is $720.0K (range $0 – $2.0M). Full-year revenue is projected at $6.9M, growing to $10.6M next year.
Have analysts been upgrading or downgrading RLAY lately?+
As of Nov 19, 2026, 10 of 11 active firms rate RLAY a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RLAY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.